Given their low frequency, a generalized screening of all meningiomas for TERT promoter mutations is considered inefficient, and the current WHO classification of brain tumors recommends targeted sampling of specimen displaying grade 2/3 borderline histological characteristics and in tumors with aggressive biological behavior [4]. The gene discussed is TERT; the disease is meningioma.